本文關(guān)鍵詞：PRDX2對結(jié)腸癌干細(xì)胞特性的調(diào)控作用及機(jī)制研究　出處：《重慶醫(yī)科大學(xué)》2017年博士論文　論文類型：學(xué)位論文

  更多相關(guān)文章： PRDX2 干細(xì)胞特性 腫瘤干細(xì)胞 Hedgehog 結(jié)腸癌

【摘要】：結(jié)腸癌是全球范圍內(nèi)的高發(fā)腫瘤之一。在我國結(jié)腸癌的發(fā)病率逐年增高,威脅到更多人的生命健康。根據(jù)中國腫瘤登記中心的統(tǒng)計數(shù)據(jù),在2015年結(jié)直腸癌新發(fā)病例估算為37.63萬人,占同年總新發(fā)腫瘤病例的8.7%,排第五位,結(jié)直腸癌死亡病例估算為19.10萬人,占同年總死亡腫瘤病例的6.8%,排第五位。目前結(jié)直腸癌的治療仍以傳統(tǒng)手術(shù)、輔助化療為主,但是中晚期結(jié)直腸癌療效并不理想,為了提升結(jié)直腸癌的治療效果,有必要深入理解結(jié)直腸癌發(fā)生發(fā)展和轉(zhuǎn)移復(fù)發(fā)的機(jī)制。對于結(jié)直腸癌的標(biāo)準(zhǔn)化治療所獲得的療效有限,目前研究認(rèn)為可能歸因于結(jié)腸癌中存在少量高耐藥低增殖的腫瘤干細(xì)胞。腫瘤干細(xì)胞具有一系列獨有的生物學(xué)特性,包括自我更新、多向分化潛能、無限增殖、轉(zhuǎn)移和耐藥,被認(rèn)為是腫瘤發(fā)生發(fā)展、侵襲轉(zhuǎn)移以及復(fù)發(fā)的“種子細(xì)胞”。腫瘤微環(huán)境是腫瘤細(xì)胞賴以生存的環(huán)境,同樣地,腫瘤干細(xì)胞也有相應(yīng)的微環(huán)境,稱為腫瘤干細(xì)胞龕,在維持腫瘤干細(xì)胞特性方面發(fā)揮重要作用。腫瘤干細(xì)胞龕中氧化還原平衡的改變有可能對干細(xì)胞特性產(chǎn)生影響。過氧化物還原酶(PRDXs)是細(xì)胞中的一個抗氧化酶超家族。在這個家族中PRDX2是一個典型的2-Cys過氧化物還原酶,研究發(fā)現(xiàn)PRDX2在結(jié)腸癌組織中表達(dá)量高于癌旁組織,而且prdx2敲減能夠抑制結(jié)腸癌細(xì)胞生長,促進(jìn)凋亡。然而prdx2作為氧化還原平衡的重要調(diào)節(jié)因子,與結(jié)腸癌干細(xì)胞特性之間的關(guān)系還沒有研究清楚。目的:探討干擾prdx2基因表達(dá)對結(jié)腸癌干細(xì)胞特性的影響及其分子機(jī)制。方法:1)免疫組化檢測10例人結(jié)腸癌組織樣本中的prdx2和cd133的蛋白表達(dá),用imageproplus軟件進(jìn)行光密度分析獲得蛋白半定量數(shù)據(jù),對兩組數(shù)據(jù)進(jìn)行pearson相關(guān)性分析;用免疫磁珠法分選結(jié)腸癌細(xì)胞中的cd133-和cd133+細(xì)胞,用流式細(xì)胞儀檢測cd133+細(xì)胞比例以鑒定分選效率;分別從三株結(jié)腸癌細(xì)胞中分選出cd133-和cd133+細(xì)胞,用westernblot檢測cd133-和cd133+細(xì)胞中prdx2、cd44和cd133的蛋白表達(dá)量;在三種結(jié)腸癌細(xì)胞系中,用免疫熒光法檢測結(jié)腸癌細(xì)胞和結(jié)腸癌干細(xì)胞微球體中prdx2和cd133的蛋白表達(dá)情況。2)建立prdx2干擾質(zhì)粒載體并用慢病毒包裝,通過westernblot外源篩選有效載體,qrt-pcr內(nèi)源驗證敲減效率;通過慢病毒轉(zhuǎn)染在三株結(jié)腸癌細(xì)胞系中分別建立空載慢病毒組(cont組)和prdx2敲減組(shprdx2組),用熒光顯微鏡觀察慢病毒轉(zhuǎn)染率,用westernblot和qrt-pcr檢測兩組細(xì)胞中prdx2在mrna和蛋白水平的差異;用流式細(xì)胞儀檢測兩組細(xì)胞中cd133+細(xì)胞的比例,用westernblot和qrt-pcr檢測兩組細(xì)胞中cd44、cd133、lgr5、cxcr4、epcam和nanog的蛋白和mrna的表達(dá)量,用成球試驗觀察兩組細(xì)胞中干細(xì)胞微球體形成數(shù)量的差異,用藥物毒性實驗檢測兩組細(xì)胞對5-fu敏感性的差異,用成瘤實驗檢測兩組中的cd133+細(xì)胞在裸鼠皮下形成移植瘤的體積差異。3)建立prdx2過表達(dá)質(zhì)粒載體并用慢病毒包裝,用westernblot鑒定其有效性;通過慢病毒轉(zhuǎn)染在三株結(jié)腸癌細(xì)胞系中分別建立空載慢病毒組(cont組)和prdx2過表達(dá)組(prdx2組),用熒光顯微鏡觀察慢病毒轉(zhuǎn)染率,用westernblot檢測兩組細(xì)胞中prdx2蛋白表達(dá)量的差異;用流式細(xì)胞儀檢測兩組細(xì)胞中cd133+細(xì)胞的比例,用westernblot檢測兩組細(xì)胞中cd44、cd133和nanog的蛋白表達(dá)量差異,用成球試驗觀察兩組細(xì)胞中干細(xì)胞微球體形成數(shù)量的差異。4)選擇ht29細(xì)胞,在空載慢病毒組(cont組)、prdx2敲減組(shprdx2組)和prdx2過表達(dá)組(prdx2組)中分別用免疫磁珠法分選出cd133+細(xì)胞,對于三個組別的cd133+細(xì)胞,用westernblot檢測hedgehog/gli1通路關(guān)鍵蛋白smo和gli1的蛋白表達(dá)量;用dmso或者smo抑制劑cyclopamine對ht29細(xì)胞進(jìn)行干預(yù)并分為dmso組和cyclopamine組,用westernblot檢測干性標(biāo)志物cd44和cd133的蛋白表達(dá)量。結(jié)果:1)在10例人結(jié)腸癌組織樣本中,prdx2和cd133的蛋白表達(dá)量之間存在線性正相關(guān)性,pearson相關(guān)系數(shù)為0.7863,p=0.007。免疫磁珠法分選出的cd133+細(xì)胞中cd133+細(xì)胞的比例為93.10%,cd133-細(xì)胞中cd133+細(xì)胞的比例為1.06%。在sw620、ht29、hct116三種結(jié)腸癌細(xì)胞系中,cd133+細(xì)胞中prdx2的蛋白表達(dá)量均顯著高于cd133-細(xì)胞,p0.05。prdx2蛋白表達(dá)主要定位在細(xì)胞質(zhì)中,cd133蛋白表達(dá)主要定位在細(xì)胞膜。2)在空載慢病毒組(cont組)和prdx2敲減組(shprdx2組)中熒光轉(zhuǎn)染率均大于95%,shprdx2組中prdx2的mrna和蛋白表達(dá)量均顯著低于cont組;與cont組相比,shprdx2組中cd133+細(xì)胞群體比例顯著降低,干細(xì)胞表面標(biāo)志物cd44、cd133、lgr5、epcam和干細(xì)胞相關(guān)轉(zhuǎn)錄因子nanog的mrna和蛋白表達(dá)量顯著減少,微球體形成量顯著減少,cd133+細(xì)胞對5-fu的敏感性顯著增加,cd133+細(xì)胞形成裸鼠皮下移植瘤的體積顯著變小,p0.05。3)在空載慢病毒組(cont組)和prdx2過表達(dá)組(prdx2組)中熒光轉(zhuǎn)染率均大于95%,prdx2組中prdx2的mrna和蛋白表達(dá)量均顯著高于cont組;與cont組相比,prdx2組中cd133+細(xì)胞群體比例顯著增高,干細(xì)胞表面標(biāo)志物cd44、cd133和干細(xì)胞相關(guān)轉(zhuǎn)錄因子nanog的蛋白表達(dá)量顯著增加,微球體形成量顯著增加,p0.05。4)在ht29細(xì)胞分選出的cd133+細(xì)胞中,與cont組相比,shprdx2組的smo和gli1蛋白表達(dá)量均顯著降低,prdx2組的smo和gli1蛋白表達(dá)量均顯著增加,p0.05;在ht29細(xì)胞系中,與dmso組相比,cyclopamine組的smo和gli1蛋白表達(dá)量均顯著降低,同時干細(xì)胞表面標(biāo)志物cd44和cd133蛋白表達(dá)量均顯著降低,p0.05。結(jié)論:prdx2可能通過hedgehog/gli1信號通路維持結(jié)腸癌干細(xì)胞特性。
[Abstract]:Colon cancer is one of the worldwide high incidence of tumors. In the pathogenesis of colorectal cancer in China increased year by year, more threat to people's lives and health. According to the statistical data of Chinese cancer registry in 2015, new cases of colorectal cancer is estimated to be 376 thousand and 300 people, accounting for the same year the total new tumors were 8.7%, fifth a colorectal cancer deaths estimated 191 thousand people, accounting for the same year the total death of the tumor was 6.8%, ranked fifth. The current treatment of colorectal cancer with traditional surgery, adjuvant chemotherapy in advanced colorectal cancer, but the effect is not ideal, to enhance the treatment effect of colorectal cancer, it is necessary to understand the mechanism of the occurrence. The development and metastasis of recurrent rectal cancer. The curative effect obtained for colorectal cancer standardized treatment is limited, current research that may be attributed to colon cancer in the presence of a small amount of high resistance low proliferation of tumor stem cells . tumor stem has a series of unique biological characteristics of cells, including self-renewal, differentiation, proliferation, metastasis and drug resistance, is considered to be the tumor development, invasion and metastasis and recurrence of the "seed cells". The tumor microenvironment is a tumor cell survival environment, similarly, tumor stem cells are also micro the environment, called cancer stem cell niche, play an important role in maintaining the characteristics of tumor stem cells. Tumor stem cell niche in the oxidation reduction equilibrium changes may influence the properties of stem cells. Reduction of peroxide enzyme (PRDXs) is a superfamily of antioxidant enzymes in the cell. In this family is PRDX2 a typical 2-Cys peroxidoxin, the study found that the expression of PRDX2 in colon cancer was higher than that in paracancerous tissue, and knockdown of prdx2 can inhibit the growth of colon cancer cells, promote apoptosis. However, PRDX 2 as an important regulator of the redox balance, and colon cancer stem cell characteristics between has not been studied clearly. Objective: To investigate the effect of prdx2 gene expression characteristics of colon cancer stem cells and its molecular mechanism. Methods: 1) was detected by immunohistochemistry in 10 cases of human colon cancer tissue samples of prdx2 and CD133 the expression of the optical density analysis of protein semi quantitative data by imageproplus software, Pearson correlation analysis was performed between the two groups of data; using immunomagnetic cell sorting in colorectal cancer cells cd133- and cd133+ cells, with the proportion of cd133+ cells by flow cytometry to identify the separation efficiency; respectively from the colon cancer cell lines by three cd133- and cd133+ cells detected by Westernblot cd133- and cd133+ prdx2 cells, expression of CD44 and CD133 protein; in three colon cancer cell lines, by immunofluorescence detection of colon cancer Cells and colon cancer stem cells prdx2 and CD133 protein microspheres in the expression of.2) to establish prdx2 interference plasmid vector and lentiviral packaging by exogenous Westernblot screening of the effective carrier, qRT-PCR knockdown of endogenous verification efficiency; establish no-load lentivirus group in three strains of colon cancer cells by lentiviral transfection (cont group) and prdx2 knockdown group (shprdx2 group), observed by fluorescence microscopy and lentiviral transfection efficiency, with the difference between Westernblot and qRT-PCR for detection of prdx2 in the two groups at the level of mRNA and protein ratio; flow cytometry cd133+ cells in two groups of cells, Westernblot and qRT-PCR in two groups were detected in CD44 cells. CD133, Lgr5, CXCR4, EpCAM expression and Nanog protein and mRNA, observe the cell number of microspheres formed in two groups of cells with different ball test, the sensitivity of 5-FU of two groups of cell drug toxicity test The difference in formation volume differences in transplantation tumor of.3 in nude mice with cd133+ cell tumor assay in two groups) to establish prdx2 over expression vector and lentiviral packaging, identification of the effectiveness of Westernblot were established; no-load lentivirus group in three strains of colon cancer cells by lentiviral transfection (cont group) and prdx2 overexpression group (prdx2 group), observed by fluorescence microscopy and lentiviral transfection rate and the expression level of prdx2 protein between two groups of cells detected by Westernblot; the proportion of using flow cytometry cd133+ cells in the two groups, two groups of CD44 cells detected by Westernblot, the expression of CD133 and Nanog the amount of protein differences were observed, mammosphere formation number difference of.4 in two groups of cells with stem ball test) HT29 cells in empty lentivirus group (cont group), prdx2 group (group shprdx2) knockdown and overexpression of prdx2 group (prdx2 group) respectively. Select the cd133+ cells by immunomagnetic beads method, for the three groups of the cd133+ cells, the expression of hedgehog/gli1 protein detected by Westernblot pathway and Gli1 protein SMO; DMSO or SMO inhibitor cyclopamine on HT29 cells were intervened and divided into DMSO group and cyclopamine group, marker CD44 expression and CD133 protein were detected by Westernblot dry. Results: 1) in 10 cases of human colon cancer tissue samples, the expression of prdx2 and CD133 protein had positive linear relationship between Pearson, the correlation coefficient was 0.7863, cd133+ cells p=0.007. immunomagnetic cell sorting of CD133 + cells in the ratio of 93.10%, cd133+ cells and cd133- cells in the ratio of 1.06%. in SW620 HT29, HCT116, three colon cancer cell lines, the expression of prdx2 protein in cd133+ cells was significantly higher than that of cd133- cells, the expression of p0.05.prdx2 protein was mainly localized in the cytoplasm, CD133 Protein expression was mainly localized in the cell membrane of.2) in empty lentivirus group (cont group) and prdx2 knockdown group (group shprdx2) fluorescence transfection rate was greater than 95%, the mRNA and protein expression of prdx2 in shprdx2 group were significantly lower than that of cont group; compared with cont group, shprdx2 group in cd133+ cell group was significantly lower stem cell surface markers CD44, CD133, Lgr5, EpCAM and mRNA protein and transcription factor Nanog related stem cell expression was significantly reduced, mammosphere Chengliang significantly reduce the sensitivity of cd133+ cells to 5-FU significantly increased the formation of cd133+ cells of nude mice subcutaneous transplantation tumor volume was significantly smaller, p0.05.3) in slow load virus group (cont group) and prdx2 group (group prdx2) expression in fluorescence transfection rate was greater than 95%, the mRNA and protein expression of prdx2 in prdx2 group was significantly higher than that of cont group; compared with cont group, prdx2 group in cd133+ group was significantly higher than in stem cells. The cell surface markers CD44, CD133 and transcription factor Nanog related stem cell protein expression was significantly increased, mammosphere Chengliang increased significantly, p0.05.4) in HT29 cells sorted cd133+ cells, compared with the cont group, the expression of SMO and Gli1 protein in shprdx2 group decreased significantly, and the expression of prdx2 group SMO and Gli1 the amount of protein was increased significantly in P0.05; HT29 cell line, compared with the DMSO group, the expression of SMO and Gli1 protein in cyclopamine group decreased significantly, while the stem cell surface marker CD44 expression and CD133 protein decreased significantly. Conclusion: prdx2 may p0.05. through hedgehog/gli1 signaling pathway to maintain the characteristics of cancer stem cell junction.

【學(xué)位授予單位】：重慶醫(yī)科大學(xué)
【學(xué)位級別】：博士
【學(xué)位授予年份】：2017
【分類號】：R735.35

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 穆寅東;張際緋;王景霞;田國忠;;結(jié)腸癌發(fā)生發(fā)展過程中結(jié)腸癌干細(xì)胞的作用[J];牡丹江醫(yī)學(xué)院學(xué)報;2013年03期

2 周瑞蓮;姚程;陳玉丙;;結(jié)腸癌干細(xì)胞的研究進(jìn)展[J];中國生物制品學(xué)雜志;2008年03期

3 David Sharp;接英;馬建華;;結(jié)腸癌干細(xì)胞研究進(jìn)展令人激動不已[J];科學(xué)觀察;2009年02期

4 陳遠(yuǎn)崇;;結(jié)腸癌干細(xì)胞表面標(biāo)志的研究和信號傳導(dǎo)[J];中國組織工程研究與臨床康復(fù);2011年45期

5 楊東;張金龍;黃軼軒;欒青春;劉健;孟希亭;王海娟;錢海利;李貴新;林晨;;干細(xì)胞培養(yǎng)基成球培養(yǎng)法篩選結(jié)腸癌干細(xì)胞的生物學(xué)特性[J];山東醫(yī)藥;2012年25期

6 郭開峰;曾云;;無血清懸浮培養(yǎng)法富集結(jié)腸癌干細(xì)胞[J];四川解剖學(xué)雜志;2012年02期

7 馮燕君;夏璐;;結(jié)腸癌干細(xì)胞標(biāo)志分子及其功能研究現(xiàn)狀[J];國際消化病雜志;2012年01期

8 孫秀梅;高峰;劉子鳳;;鹽霉素對結(jié)腸癌干細(xì)胞特性的抑制作用[J];山東大學(xué)學(xué)報(醫(yī)學(xué)版);2013年09期

9 趙景鋒;龔代平;卿松;楊川;楊秀江;;結(jié)腸癌干細(xì)胞的研究進(jìn)展與在臨床治療中的意義[J];重慶醫(yī)學(xué);2014年23期

10 陳志剛;黃建;;結(jié)腸癌干細(xì)胞研究進(jìn)展[J];實用腫瘤雜志;2010年01期

相關(guān)博士學(xué)位論文 前4條

1 馮飛雪;NF-κB介導(dǎo)的Rab27A表達(dá)上調(diào)促進(jìn)結(jié)腸癌干細(xì)胞的干性[D];第四軍醫(yī)大學(xué);2014年

2 王榮;PRDX2對結(jié)腸癌干細(xì)胞特性的調(diào)控作用及機(jī)制研究[D];重慶醫(yī)科大學(xué);2017年

3 冷政偉;KLF4在富集結(jié)腸癌干細(xì)胞的球細(xì)胞中發(fā)揮原癌作用[D];華中科技大學(xué);2013年

4 艾亮;RNA干擾CD133基因?qū)θ私Y(jié)腸癌干細(xì)胞生物學(xué)特性的影響[D];重慶醫(yī)科大學(xué);2010年

相關(guān)碩士學(xué)位論文 前9條

1 吳明發(fā);CD151對人結(jié)腸癌干細(xì)胞裸鼠移植瘤生長作用及機(jī)制的研究[D];河北醫(yī)科大學(xué);2015年

2 羅子華;長鏈非編碼RNA—LOCCS對人結(jié)腸癌干細(xì)胞增殖和分化的調(diào)控機(jī)制[D];復(fù)旦大學(xué);2014年

3 于杰;負(fù)載結(jié)腸癌干細(xì)胞gp96-肽復(fù)合物DC-CIK對同源腫瘤干細(xì)胞殺傷作用的初步研究[D];天津醫(yī)科大學(xué);2015年

4 徐媛媛;結(jié)腸癌干細(xì)胞的篩選及其耐藥性研究[D];吉林大學(xué);2010年

5 韓博;20（S）-人參皂苷Rg3誘導(dǎo)結(jié)腸癌干細(xì)胞凋亡及其機(jī)制的初步研究[D];吉林大學(xué);2013年

6 周寧;結(jié)腸癌干細(xì)胞抗原致敏的樹突狀細(xì)胞誘導(dǎo)抗腫瘤免疫應(yīng)答的研究[D];吉林大學(xué);2015年

7 夏國盛;幾種藥物代謝相關(guān)蛋白基因在結(jié)腸癌細(xì)胞中的表達(dá)與化療敏感性的相關(guān)性[D];南方醫(yī)科大學(xué);2009年

8 宓林;酵母雙雜交篩選stratifin在結(jié)腸癌干細(xì)胞中相互作用的蛋白質(zhì)[D];復(fù)旦大學(xué);2013年

9 鄧超;結(jié)腸癌干細(xì)胞的培養(yǎng)鑒定與體外成瘤特征以及馬齒莧提取物對結(jié)腸癌干細(xì)胞干預(yù)作用的機(jī)理研究[D];南京中醫(yī)藥大學(xué);2015年

，

本文編號：1365595